{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 1,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "## Retrieval augmented generation\n",
    "\n",
    "import os\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\python312.zip', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\DLLs', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\Lib', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv', '', 'C:\\\\Users\\\\Admin\\\\AppData\\\\Roaming\\\\Python\\\\Python312\\\\site-packages', 'C:\\\\Users\\\\Admin\\\\AppData\\\\Roaming\\\\Python\\\\Python312\\\\site-packages\\\\win32', 'C:\\\\Users\\\\Admin\\\\AppData\\\\Roaming\\\\Python\\\\Python312\\\\site-packages\\\\win32\\\\lib', 'C:\\\\Users\\\\Admin\\\\AppData\\\\Roaming\\\\Python\\\\Python312\\\\site-packages\\\\Pythonwin', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\Lib\\\\site-packages', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\Lib\\\\site-packages\\\\win32', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\Lib\\\\site-packages\\\\win32\\\\lib', 'c:\\\\Users\\\\Admin\\\\.conda\\\\envs\\\\venv\\\\Lib\\\\site-packages\\\\Pythonwin']\n"
     ]
    }
   ],
   "source": [
    "import sys\n",
    "print(sys.path)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "os.environ['OPENAI_API_KEY']=os.getenv(\"OPENAI_API_KEY\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.core import VectorStoreIndex,SimpleDirectoryReader\n",
    "documents=SimpleDirectoryReader(\"RP\").load_data()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Document(id_='050b73b4-6405-478b-bb8a-a479b9a5a346', embedding=None, metadata={'page_label': '1', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text=\"Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 118   \\nInnovations in AI-Powered Healthcare: Transforming Cancer Treatment \\nwith Innovative Methods \\n1Saad Rasool, 2Mohammad Ali, 3Hafiz Muhammad Shahroz, 4Hafiz Khawar Hussain, 5Ahmad Yousaf Gill \\n1Department of computer science, Concordia University Chicago, 7400 Augusta St, River Forest, IL 60305, \\nUnited States, 2Independent Researcher Iraq, 3Universit√§t Cottbus-Senftenberg Germany, 4DePaul University \\nChicago, Illinois, USA, 5 American National University 1814 E Main St Salem VA 24153 \\n1crf_rasools@cuchicago.edu, 2m.ali.m2000m@gmail.com, 3spyapp@gmail.com, \\n4Khawar.hussain78@gmail.com, 5ahmadgill436@gmail.com \\n \\nAbstract:  In this thorough review, we explore the multifaceted role of artificial intelligence (AI) in cancer medicine, \\nhighlighting its potential applications, challenges, and future directions. Artificial intel ligence (AI) holds enormous promise \\nfor revolutionizing patient care and improving outcomes when integrated into various aspects of cancer medicine, including \\ndrug discovery and development, early detection and screening, and drug discovery.  AI-driven methods in early detection and \\nscreening can increase sensitivity, decrease false-positive rates, and provide personalized risk assessment, which can boost the \\nefficacy and efficiency of cancer screening programs. However, issues like algorithm bias, data qua lity, and regulatory \\ncompliance need to be resolved before AI can be fully utilized in this field.  In addition, AI -driven drug discovery and \\ndevelopment offers chances to speed up target identification, repurpose current medications, and create new therap eutics with \\nimproved safety and efficacy profiles. However, even with AI's potential to speed up drug discovery, issues with data \\naccessibility, algorithm interpretability, and ethical implications still exist.  Researchers, clinicians, regulators, and ind ustry \\nstakeholders must work together to develop strong data -sharing initiatives, ethical guidelines, and governance frameworks in \\norder to address these challenges. By putting patient-centered approaches first, integrating multi-modal data, and encouraging \\ninterdisciplinary collaboration, we can harness the transformative power of AI to speed up the translation of research findin gs \\ninto novel therapies and enhance global cancer patient outcomes.  \\nKey words: AI, or artificial intelligence , Cancer Treatment,  Early Recognition, Examining, Medication discovery, Drug  \\nResearch, Identification of the Target, Individualized Medical Care, Integration of Multi-Omics, Algorithmic Prejudice,  \\nINTRODUCTION \\nThis section gives an overview of AI technologies, their significance in addressing challenges in cancer medicine, \\nand the potential implications for the future of oncology. Artificial intelligence (AI) has emerged as a \\ntransformative force in healthcare, revolutionizing various aspects of medical practice, including diagnosis, \\ntreatment, and patient care. In the context of cancer medicine, AI holds immense promise for improving outcomes, \\nenhancing precision, and streamlining workflows [1].  \\nSynopsis of Art ificial Intelligence Technologies:  Artificial Intelligence (AI) is a broad term that refers to a \\nvariety of technologies that allow machines to do tasks like learning, reasoning, and problem solving that are \\nnormally performed by humans. Machine learning (ML), a subset of AI, is the process of teaching algorithms to \\nidentify patterns in data and make predictions. Deep learning, a more advanced application of ML, uses artificial \\nneural networks to process large amounts of data and extract complex features [ 2].  AI is being used in a wide \\nrange of healthcare domains, such as medical imaging, clinical decision support, genomics, and drug discovery. \\nTo help radiologists identify abnormalities, characterize tumors, and track the progression of diseases,  \\nAI algorithms can analyze radiological images, such as X-rays, CT scans, and MRIs. These algorithms can identify \\nsubtle patterns or anomalies that may not be visible to the human eye, improving the accuracy and efficiency of \\ndiagnosis. AI-driven clinical decision support systems also incorporate patient data, expert knowledge, and medical \\nliterature to help healthcare providers make evidence -based decisions. These systems can help physicians create \\ntreatment plans, forecast patient outcomes, and find individualize d treatment options based on the traits and \\npreferences of specific patients [3].  \\nAI's Critical Role in Overcoming Obstacles in Cancer Medicine: Millions of people die from cancer every \\nyear, making it one of the biggest global public health concerns. Despite advances in research and treatment, cancer \\ndiagnosis and management are still intricate and multidimensional, frequently requiring interdisciplinary \\nteamwork and individualized approaches.  AI-based screening algorithms can analyze medical images or \\nbiomarker data to identify suspicious lesions or patterns indicative of cancer, enabling early intervention and \\nimproving prognosis [4]. Early detection and diagnosis is one of the primary challenges in cancer medicine, as \\nmany cancers are asymptomatic in t he early stages, making timely diagnosis difficult. AI -based screening \\nalgorithms offer unique capabilities to address these key challenges.  \\nAI can also help with precision oncology by using genomic data and molecular profiles to group patients into \\nsubgroups according to their genetic composition and the characteristics of their tumors. This personalized \", path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='f0d283fd-ef62-4a7e-9545-ec4b2de0d4b9', embedding=None, metadata={'page_label': '2', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text=\"Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 119   \\napproach helps oncologists to customize treatment plans for each patient, increasing therapeutic efficacy while \\nreducing side effects.  Based on clinical  and genetic data, AI-powered predictive modeling can predict treatment \\nresults, disease progression, and patient survival. These predictive models can help with treatment choices, \\nresource allocation, and the development of patient counseling and shared d ecision-making [5].  \\nUSE OF AI IN CANCER DIAGNOSIS  \\nThe diagnosis of cancer is a crucial point in patient care that affects prognosis, treatment choices, and overall \\nresults. Conventional diagnostic approaches mainly rely on imaging modalities, histopathol ogical analysis, and \\nmolecular testing, which can take a long time and require specialized knowledge. However, in recent years, \\nartificial intelligence (AI) has revolutionized cancer diagnosis by providing sophisticated tools and techniques to \\nimprove accuracy, efficiency, and early detection. This section provides an overview of the various applications \\nof AI in cancer diagnosis [6]. \\nMedical Imaging and Image Analysis:  Medical imaging is essential for the diagnosis of cancer because it gives \\ndoctors important information about the location, size, and morphology of tumors. However, interpreting imaging \\nstudies can be difficult and need specific knowledge and training. Artificial intelligence (AI)-driven image analysis \\nalgorithms use machine learning techniques to analyze radiological images, including CT, MRI, PET, and X-rays.  \\nMoreover, AI -powered image segmentation algorithms can precisely define tumor boundaries and surrounding \\nanatomical structures, enabling treatment planning and surgical navigation. Th ese algorithms can automatically \\ndetect and characterize suspicious lesions, quantify tumor size and growth rate, and evaluate treatment response \\n[7].  \\nAlgorithms for early detection and screening: AI-driven screening algorithms use machine learning and pattern \\nrecognition to analyze different kinds of data, such as imaging studies, biomarker measurements, and patient \\ndemographics. These algorithms can identify subtle patterns or anomalies indicative of early -stage cancer, often \\nbefore symptoms manifest or conventional diagnostic tests detect abnormalities. Early detection is crucial to \\nimproving cancer outcomes because it allows for timely intervention and treatment initiation [8].  Artificial \\nintelligence (AI) has demonstrated potential in enhancing the sensitivity and specificity of breast cancer screening \\nsystems, thereby decreasing false positives and needless biopsies. \\nInterpretation of Pathology and Histopathology:  Although histopathological analysis is still the gold standard \\nfor diagnosing cancer, i t can be time -consuming and subjective to manually interpret histopathological slides, \\nwhich can lead to variations in diagnostic precision. Histopathological analysis provides important information \\nabout tumor morphology, grade, and molecular characterist ics. To address these issues, deep learning algorithms \\ntrained on massive datasets of annotated histopathological images can accurately classify tissue specimens, identify \\ntumor regions, and predict prognostic markers. AI -powered digital pathology platform s automate slide scanning, \\nimage analysis, and diagnosis.  AI-driven image analysis can also reveal molecular signatures and subtle \\nhistological features that are not visible to human observers, improving prognostic assessment and diagnostic \\naccuracy [9]. These developments in digital pathology have the potential to transform cancer diagnosis by \\nincreasing precision, reproducibility, and efficiency.  \\nAI-POWERED PRECISION CANCER CARE  \\nThis section examines the various applications of AI -driven precision oncology, including genomic analysis, \\npersonalized treatment strategies, and targeted therapies. Precision oncology is a revolutionary approach to cancer \\ncare that focuses on identifying molecular alterations within tumors and tailoring treatment strategies to individual \\npatients' unique genetic profiles. Artificial intelligence (AI) plays a pivotal role in advancing precision oncology \\nby analyzing complex genomic data, predicting treatme nt response, and guiding personalized therapeutic \\ninterventions [10].  \\nBioinformatics and Molecular Identification: High-throughput sequencing technologies have revolutionized our \\nunderstanding of cancer biology by allowing for the identification of action able genetic alterations and \\ncomprehensive genomic characterization of tumors. Nevertheless, oncologists face significant challenges in \\nanalyzing large amounts of genomic data and determining their clinical relevance.  These algorithms can analyze \\ngenomic sequences, gene expression profiles, and somatic mutations to stratify patients into molecular subtypes, \\npredict disease progression, and inform therapeutic decision -making. AI algorithms, in particular deep learning \\nmodels, excel in extracting meaningful insights from complex genomic datasets, uncovering patterns, and \\nidentifying predictive biomarkers associated with treatment response and disease prognosis [11].  To build \\nmolecular profiles of individual tumors and identify potential therapeutic targets, for example, AI -driven \\nbioinformatics platforms can integrate multi-omics data, such as transcriptomics, proteomics, and genomics. These \", path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='66b770e2-761f-47a6-a860-5308ac606606', embedding=None, metadata={'page_label': '3', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text=\"Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 120   \\nplatforms can also corroborate genomic alterations with drug sensitivity databases and clinical outcomes, making \\nit easier to select targeted therapies or clinical trials that are customized to patients' unique molecular profiles.  \\nTailored Intervention Techniques:  By customizing treatment regimens to each patient's unique molecular \\ncharacteristics, preferences, and clini cal parameters, precision oncology seeks to overcome the limitations of \\ntraditional cancer treatments, which frequently take a one -size-fits-all approach, resulting in variable responses \\nand significant toxicity in some patients [12]. AI -driven decision support systems can analyze complex datasets, \\nidentify therapeutic vulnerabilities, and predict the likelihood of response to individual drugs or combination \\ntherapies. These systems use patient -specific data, including genomic profiles, clinical history, im aging studies, \\nand treatment responses, to recommend personalized treatment strategies.  By continuously learning from real -\\nworld patient data and clinical outcomes, AI algorithms can optimize treatment sequencing and dosing schedules \\nto maximize therapeutic efficacy while minimizing side effects. Over time, these algorithms can refine treatment \\nrecommendations, adapting to changing tumor dynamics and patient preferences [13].  \\nDrug Discovery and Targeted Therapy:  Precision oncology's cornerstone, targeted therapies, aims to block \\nparticular molecular pathways that fuel tumor growth and metastasis. AI -driven methods are speeding up the \\nprocess of finding and developing targeted therapies by examining biological networks, drug -gene interactions, \\nand large-scale genomic datasets.  AI-powered drug discovery platforms expedite the identification of promising \\ntherapeutic candidates and aid in the development of more potent anticancer agents by simulating drug responses \\nin silico and validating predictions in vitro  and in vivo. For instance, AI algorithms can predict novel drug -target \\ninteractions, identify druggable vulnerabilities in cancer cells, and prioritize candidate compounds for preclinical \\ntesting [14].  \\nAI-ENHANCED CANCER TREATMENT  \\nArtificial intelligence (AI) is revolutionizing cancer treatment by providing cutting -edge tools and techniques to \\nenhance treatment planning, real -time monitoring, and predictive modeling. This section explores the various \\napplications of AI in enhancing cancer treatment, incl uding treatment planning and optimization, real -time \\nmonitoring, and predictive modeling for treatment outcomes. Cancer treatment is a multifaceted endeavor that \\nrequires precise planning, continuous monitoring, and adaptive interventions to maximize patie nt outcomes [15].  \\nPlanning and Optimizing Treatment:  The process of choosing the best therapeutic modalities, dosages, and \\nsequences for each patient's unique disease characteristics, preferences, and comorbidities is known as treatment \\nplanning, and it has historically been based on expert judgment and empirical guidelines, which has resulted in \\ninconsistent clinical decision-making and, in certain cases, suboptimal outcomes [16].  AI-driven decision support \\nsystems can analyze complex datasets, identify treatment vulnerabilities, and predict the likelihood of response to \\nparticular therapies or combination regimens.  \\nAdaptive therapies with real-time monitoring: Conventional monitoring methods, such as imaging studies and \\nbiomarker assessments, often pro vide incomplete or delayed information, limiting their utility in guiding timely \\nclinical decisions. Real -time monitoring of treatment response is crucial for evaluating treatment efficacy, \\nidentifying early signs of disease progression, and guiding adaptive interventions.  AI algorithms can analyze serial \\nimaging studies, such as magnetic resonance imaging (MRI) or positron emission tomography (PET) scans, to \\ndetect subtle changes in tumor size, morphology, or metabolic activity indicative of treatment res ponse or disease \\nprogression [17]. AI -driven monitoring systems use advanced imaging techniques, molecular biomarkers, and \\nmachine learning algorithms to provide real-time feedback on treatment response and disease progression.  \\nAdditionally, circulating t umor DNA (ctDNA), circulating tumor cells (CTCs), and other biomarkers in blood \\nsamples can be analyzed by AI -powered liquid biopsy platforms to track response to treatment, find minimally \\nresidual disease, and pinpoint emerging resistance mechanisms. Thes e platforms capture dynamic changes in \\ntumor biology and genomic evolution, allowing for early intervention and treatment adaptation to maximize \\ntherapeutic outcomes.  Real-time clinical data‚Äîsuch as treatment toxicities, adverse events, and patient -reported \\noutcomes‚Äîcan be integrated by AI-driven decision support systems to direct adaptive interventions and supportive \\ncare measures [18]. These systems can also help by early detection of treatment -related complications or side \\neffects, which allows for timely modifications to treatment regimens, dose adjustments, or supportive interventions \\nto improve patient comfort and adherence.  \\n \\n \", path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='05f53528-0202-499f-a9bb-0f7c74999649', embedding=None, metadata={'page_label': '4', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text=\"Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 121   \\nPREDICTIVE MODELING OF THERAPY RESULTS \\nAI algorithms can analyze a variety of datasets, including clinical parameters, genomic profiles, imaging features, \\nand treatment histories, to predict treatment response, disease progression, and patient survival probabilities. \\nPredictive modeling is essential for foretelling treatment outcomes, directing clinical decision -making, and \\ninforming patient counseling.  AI-driven predictive models, for instance, can forecast personalized outcomes, like \\noverall survival (OS), progression -free survival (PFS), or toxicities associated with treatment, based on tumor \\nbiology and patient -specific characteristics [19]. These models combine complex interactions between multiple \\nvariables, including genetic mutations, tumor histology, treatment regimens, and patient demographics, to produce \\nprecise prognostic estimates.  AI -powered predictive models can s upport shared decision -making by offering \\ntailored risk assessments and treatment recommendations to patients and healthcare providers. These models \\nquantify the possible advantages and disadvantages of various treatment options, enabling patients to make \\ndecisions that are in line with their values, preferences, and treatment objectives.  \\nAI algorithms can also find prognostic biomarkers or therapeutic targets linked to resistance or response to \\ntreatment, which can lead to the creation of new predictive s ignatures or biomarker panels. These biomarkers can \\nalso be used to stratify patients into groups with different outcomes or responses to treatment, which can inform \\ntailored therapeutic interventions and precision medicine strategies [20].  AI -powered tec hnologies offer \\nsophisticated tools and techniques to improve patient outcomes, enhance clinical decision -making, and optimize \\nhealthcare delivery in oncology settings. However, realizing the full potential of AI in cancer treatment requires \\naddressing various challenges, including data integration, interoperability, regulatory considerations, and clinical \\nimplementation. Nevertheless, the integration of AI technologies holds promise for revolutionizing cancer care \\nand advancing towards more precise, person alized, and effective treatment s. Conclusion: AI -driven approaches \\nare transforming cancer treatment by enhancing treatment planning, real -time monitoring, and predictive \\nmodeling.  \\nREGULATORY AND ETHICAL CONSIDERATIONS  \\nIn order to ensure patient safety,  privacy, and fair access to cutting -edge technologies, a number of ethical and \\nregulatory issues are raised by the continued advancement of artificial intelligence (AI) in healthcare, particularly \\nin the area of cancer medicine. This section explores these issues, discussing the ethical implications of AI-driven \\nhealthcare solutions, the regulatory frameworks governing their implementation, and the necessity of responsible \\nAI development in the context of cancer medicine [21]. \\nData security and patient pri vacy:  AI algorithms rely on large amounts of patient data, including genomic \\nprofiles, imaging studies, electronic health records (EHRs), and clinical outcomes to train and optimize their \\nperformance. However, this reliance raises concerns about data breaches, unauthorized access, and potential \\nmisuse of patient information. Protecting patient privacy and the security of sensitive medical data is one of the \\nmain issues surrounding AI in healthcare.  Strict data protection measures, such as encryption, anonymization, and \\naccess controls to protect patient confidentiality, must be put in place to address these concerns [22]. Additionally, \\nhealthcare organizations must follow legal requirements, such as  the United States' Health Insurance Portability \\nand Accountability Act (HIPAA), to guarantee adherence to ethical standards and data privacy laws.  \\nLegislative Structures for AI in Medicine:  Regulators must strike a balance between fostering innovation a nd \\nsafeguarding patient welfare, while also addressing unique challenges posed by AI in healthcare, such as \\nalgorithmic bias, interpretability, and accountability. As a result, existing regulatory frameworks may lag behind \\nthe rapid pace of AI innovation, posing challenges for policymakers, healthcare providers, and technology \\ndevelopers alike. Regulatory oversight is essential to ensuring the safety, effectiveness, and ethical use of AI -\\ndriven healthcare technologies.  The FDA, for instance, has released a regulatory framework for AI-based medical \\ndevices that outlines requirements for premarket approval, post -market surveillance, and quality assurance. \\nSimilarly, the European Union's Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR)  \\nimpose regulatory requirements on AI -driven medical devices to ensure safety, efficacy, and data protection. In \\nrecent years, regulatory agencies around the world have started to develop guidelines and frameworks specifically \\ntailored to AI in healthcare [23].  \\nThe Ethical Consequences of AI -Powered Cancer Treatment: Artificial intelligence (AI) in the context of \\ncancer medicine raises special ethical questions about diagnosis, treatment choices, and patient care. For example, \\nusing AI algorithms for progn ostication and risk prediction may give rise to questions about algorithmic bias, \\naccountability, and fairness; biased algorithms trained on unbalanced or unrepresentative datasets may perpetuate \\nhealthcare delivery disparities by granting unequal access t o diagnostic tests, treatments, or clinical trials.  \\nHealthcare providers should use caution when relying on AI recommendations, making sure that they are consistent \", path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='d9484d5d-86eb-4fbc-9ca2-50e028a54642', embedding=None, metadata={'page_label': '5', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text=\"Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 122   \\nwith clinical guidelines, evidence-based medicine, and patient preferences [24]. Additionally, the integration of AI \\ninto clinical decision -making processes may challenge established norms of medical practice, raising questions \\nabout professional autonomy, accountability, and liability.  Healthcare organizations must navigate the complex \\nlandscape of partnerships, collaborations, and vendor relationships while prioritizing patient welfare and ethical \\nintegrity. In addition, the commercialization of AI -driven healthcare technologies may raise concerns about \\nindustry influence, conflicts of interest, and patient exploitation [25].  \\nNEW DIRECTIONS IN AI-ASSISTED CANCER RESEARCH \\nThe field of AI and cancer research is fast -moving, marked by breakthrough discoveries, interdisciplinary \\ncollaboration, and constant innovation. A number of new trends are i nfluencing how AI will be used in cancer \\ntreatment in the future, such as: \\nMulti-omics Integration:  Comprehensive molecular profiling of tumors and the clarification of intricate \\nbiological mechanisms underlying cancer initiation, progression, and therapeu tic response are potential outcomes \\nof integrating diverse omics data, such as transcriptomics, proteomics, metabolomics, and genomics.  Improved \\ninterpretability and openness of AI algorithms are critical for establishing confidence, encouraging clinician  \\nacceptance, and expediting regulatory approval [26],[27]. Explainable AI approaches seek to clarify the decision -\\nmaking procedures of opaque models so that physicians can comprehend and verify AI suggestions.  \\nFederated Learning:  This decentralized approa ch to AI model development fosters collaboration among \\ninstitutions while maintaining data privacy and security. Federated learning enables collaborative model training \\nacross distributed datasets without centralizing sensitive patient data, addressing privacy concerns and data-sharing \\nlimitations [28].   \\nClinical trials and real-world data: Using real-world data from wearables, electronic health records, and patient-\\ngenerated health data (PGHD) can help with real-time monitoring, predictive modeling, and outcome analysis. AI \\nintegration can also speed up the design and recruitment of clinical trials, improve patient recruitment, and optimize \\ntrial protocols.  Engaging patients as partners in AI development and implementation ensures that AI technologies \\nmeet their needs and address their concerns [29]. Patient -Centric AI: Prioritizing patient -centered care and \\nincorporating patient -reported outcomes (PROs) into AI -driven decision support systems enables personalized \\ntreatment recommendations aligned with patients' values, preferences, and treatment goals.  \\nUNSOLVED PROBLEMS AND DIFFICULTIES \\nAI has great potential in the field of cancer care, however in order to fully fulfill its potential and reduce any \\nhazards, a number of outstanding concerns and challenges need to be addressed:  \\nAlgorithmic bias and fairness: Bias in AI algorithms can perpetuate existing disparities in healthcare outcomes \\nand exacerbate health inequities among underserved populations. Therefore, addressing algorithmic bias, fairness, \\nand accountability is crucial for mitigating disparities in healthcare delivery and ensuring equitable access to AI -\\ndriven technologies [30].  \\nRegulatory and Ethical Considerations:  Responsible AI deployment in healthcare requires the development of \\nregulatory frameworks that strike a balance between innovation and patient safety, privacy, and ethical integrity \\n[31]. Regulatory agencies must modify current regulations to address the particular difficulties presented by AI -\\ndriven medical devices, decision support systems, and digital therapeutics.  \\nClinical Validation and Implementation:  Developing strong assessment criteria, carrying out prospective \\nclinical trials, and involving stakeholders in AI implementation are essential steps towards successful clinical \\nadoption. Scalability, usability, and clinical utility are challenges associated with validating AI algorithms in real-\\nworld clinical settings and integrating them into routine clinical workflows [32].  \\nHuman-Machine Collaboration: To promote cooperation between medical professionals and AI systems, trust, \\nopenness, and communication concerns need to be addressed. Physicians should have faith in AI suggestions, be \\naware of their limitations, and retain control over their own decision-making [33].  \\n \\n \\n \", path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='df0bdb27-6ab5-4ebb-b9e8-5da84c0eb421', embedding=None, metadata={'page_label': '6', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text='Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 123   \\nPOSSIBLE DIRECTIONS FOR ADVANCEMENT \\nSeveral possible avenues for advancement can be followed in order to overcome these obstacles and realize the \\nfull promise of AI in cancer medicine:  \\nInterdisciplinary Collaboration:  Knowledge exchange  and interdisciplinary teamwork are facilitated by \\ninterdisciplinary training programs, collaborative research initiatives, and shared resources [34]. Fostering \\ncollaboration amongst clinicians, data scientists, engineers, and policymakers accelerates the translation of AI \\nresearch into clinical practice and fosters cross-disciplinary innovation.  \\nEthical AI Development: Governance frameworks, interdisciplinary discourse, ethical guidelines, and inclusion, \\ndiversity, and equity principles incorporate ethica l considerations into AI development processes to ensure \\nresponsible AI deployment and mitigate potential harms [35].  International collaboration, regulatory sandboxes, \\nand mutual recognition agreements promote regulatory harmonization and facilitate mark et access for innovative \\nAI solutions.  \\nRegulatory Harmonization:  Harmonizing regulatory standards and interoperability requirements across \\njurisdictions streamlines the regulatory approval process and facilitates global adoption of AI -driven healthcare \\ntechnologies [36].  \\nEducation and Training:  Continuing education programs, professional development courses, and \\ninterdisciplinary workshops bridge the gap between AI research and clinical implementation [37]. By offering \\neducation and training opportunities  in AI literacy, data science, and digital health, healthcare professionals are \\nbetter equipped to use AI technologies in clinical practice.  \\nPatient Advocacy and Engagement: Patient advocacy groups, community outreach programs, and participatory \\ndesign approaches amplify patient voices and promote patient -centered AI solutions. By empowering patients as \\npartners in AI development and implementation, it ensures that AI technologies meet their needs, preferences, and \\npriorities.  As a result, the field of AI -driven cancer medicine has a bright future ahead of it that promises to \\nrevolutionize clinical practice, advance medical research, and improve patient outcomes [38]. But in order to fully \\nrealize this promise, unresolved issues must be addressed, obstacles must be overcome, and collaborative, patient-\\ncentered approaches to AI development and implementation must be pursued. These approaches include \\ninterdisciplinary collaboration, ethical AI development, harmonizing regulatory standards, and involving patie nts \\nas partners.  \\nPROSPECTS FOR THE FUTURE AND POSSIBLE CONSEQUENCES \\nAnticipating a bright future for transformative innovation and improvements in patient care, AI -driven cancer \\nmedicine is ripe with opportunities. Trends like multi -omics integration, exp lainable AI, federated learning, and \\npatient-centric AI are likely to influence the next wave of AI-driven healthcare technologies, which will allow for \\nmore accurate, individualized, and patient -centered approaches to cancer diagnosis and treatment.  Real izing the \\nfull potential of AI in oncology also requires addressing outstanding problems and obstacles like data quality, \\nalgorithmic bias, regulatory harmonization, and patient engagement. By encouraging interdisciplinary \\ncollaboration, ethical AI development, and patient participation in healthcare decision-making, we can harness the \\ntransformative power of AI to transform cancer care and enhance the lives of patients everywhere [39].  \\nTo sum up, the incorporation of artificial intelligence (AI) into cancer medicine is a revolutionary step in the fight \\nagainst cancer. It presents previously unheard-of chances to improve patient outcomes, progress medical research, \\nand revolutionize clinical practice. By harnessing the power of AI -powered technologies, we can surmount long-\\nstanding obstacles in cancer diagnosis, treatment, and management, ultimately leading to increased survival rates, \\ndecreased healthcare inequalities, and improved quality of life for cancer patients [40].  To guarantee the safe, \\nefficient, and fair application of AI technologies in oncology, we must prioritize ethical principles, patient-centered \\ncare, and responsible AI development as we negotiate the complexities of AI -driven healthcare. By welcoming \\ninnovation, encouraging teamwork, and adhering to ethical standards, we can fully utilize AI to transform cancer \\ncare and usher in a new era of precision medicine for the benefit of patients and society at large.  \\n \\n ', path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='164724af-aff1-4bad-8367-052007ca69ee', embedding=None, metadata={'page_label': '7', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text='Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 124   \\nRESOLVING ETHICAL CONUNDRUMS IN AI-POWERED CANCER \\nTREATMENT  \\nAI technologies h old immense promise for improving cancer diagnosis, treatment, and management, they also \\nraise complex ethical questions related to privacy, transparency, bias, and accountability. This section explores the \\nethical dilemmas inherent in AI -driven cancer med icine and proposes strategies for addressing them in a \\nresponsible and ethical manner. The integration of artificial intelligence (AI) into cancer medicine raises a number \\nof ethical considerations and dilemmas that must be carefully addressed to ensure pa tient safety, autonomy, and \\njustice [41].  \\nData security and privacy: AI algorithms rely on large amounts of patient data, including genomic profiles, \\nimaging studies, electronic health records (EHRs), and clinical outcomes to train and optimize their perf ormance; \\nhowever, the collection, storage, and utilization of such data raises concerns about data breaches, unauthorized \\naccess, and potential misuse. Protecting patient privacy and the security of sensitive medical data is one of the \\nmain ethical concerns surrounding AI in cancer medicine.  Strict data privacy laws, such as the Health Insurance \\nPortability and Accountability Act (HIPAA) in the United States, must be followed by healthcare organizations in \\norder to address these concerns. Strong data prote ction measures must be put in place to protect patient \\nconfidentiality and guarantee data security [42]. Access controls, encryption, and anonymization are crucial tools \\nfor protecting sensitive medical information and preventing unauthorized disclosure.  \\nOpenness and Responsibility: The lack of accountability and transparency in the decision -making processes of \\nAI algorithms presents another ethical conundrum in AI -driven cancer care. Since many AI models function as \\n\"black boxes,\" or opaque internal workings that are hard to understand, clinicians and patients may find it difficult \\nto understand how AI algorithms arrive at their recommendations, raising questions about clinical autonomy, trust, \\nand accountability.  In order to allay these worries, efforts should be made to improve the explain ability and \\ntransparency of AI algorithms in the field of cancer medicine. The goal of explainable AI (XAI) approaches is to \\nshed light on the decision -making procedures of black -box models, giving patients and physici ans a better \\nunderstanding of how AI recommendations are made. By improving the interpretability and transparency of AI \\nalgorithms, physicians will be better equipped to recognize the limitations of these algorithms, evaluate their \\ndependability, and make well-informed decisions regarding patient care [43].  \\nFairness and Bias:  In AI-driven cancer medicine, biased algorithms trained on unbalanced or unrepresentative \\ndatasets may perpetuate disparities in cancer diagnosis, treatment, and outcomes, resulting in unequal access to \\nhealthcare services and aggravating health inequities among marginalized populations. Algorithmic bias is another \\nethical challenge that has implications for equity, fairness, and justice in the delivery of healthcare. Fairness-aware \\nmachine learning techniques seek to identify and mitigate biases in AI algorithms, ensuring that they do not \\ndisproportionately impact certain demographic groups or perpetuate existing disparities [44]. Additionally, diverse \\nand inclusive datasets that reflect the demographic diversity of patient populations are crucial for training unbiased \\nAI models and enhancing the generalizability of AI -driven healthcare solutions. These actions are necessary to \\naddress algorithmic bias in AI-driven cancer medicine.  \\nAI\\'S ADVANTAGES FOR EARLY DETECTION AND SCREENING  \\nIncreased Sensitivity and Specificity: Artificial intelligence (AI) algorithms have the ability to analyze intricate \\npatterns and features in medical imaging studies, including computed tomography (CT) scans, magnetic resonance \\nimaging (MRI), and mammograms, with a sensitivity and specificity that is greater than that of conventional \\nmethods. AI -powered screening tools can identify at -risk individuals earlier in the course of the disease by \\nidentifying subtle abnormalities and early signs of cancer [45].  \\nReduced False-Positive Rates: AI algorithms can help mitigate false -positive results by differentiating between \\nbenign and malignant lesions based on imaging characteristics, clinical data, and risk stratific ation models. By \\nreducing false positives, AI -driven screening tools can optimize resource allocation, streamline workflows, and \\nimprove the overall efficiency of screening programs. The high rate of false -positive findings is one of the major \\nchallenges in cancer screening and can result in unnecessary diagnostic procedures, patient anxiety, and healthcare \\ncosts [46].  \\nPersonalized Risk Assessment:  By classifying patients into risk groups, AI -driven screening programs can \\ncustomize screening tactics and in tensity to individualized risk profiles, optimizing the use of resources and \\nmaximizing the efficacy of screening initiatives. Based on demographic characteristics, lifestyle variables, genetic \\npredisposition, and biomarker profiles, AI -powered risk predic tion models can evaluate each patient\\'s risk of \\ndeveloping cancer [47].  ', path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='c8d12ecd-6a53-45f9-b678-7a4a56196f14', embedding=None, metadata={'page_label': '8', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text=\"Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 125   \\nIntegration of Multi -Modal Data:  By utilizing multi -modal data fusion techniques, AI -driven screening tools \\ncan capture complex interactions between genetic, environmental, and clinical factors, improving the accuracy and \\nreliability of risk prediction models. AI algorithms can integrate diverse data sources, including imaging studies, \\ngenomic data, electronic health records (EHRs), and patient -reported outcomes, to provide comprehensi ve risk \\nassessment and personalized screening recommendations [48].  \\nOBSTACLES & THINGS TO THINK ABOUT \\nData Quality and Standardization:  Variability in imaging protocols, data formats, and annotation practices \\nacross healthcare institutions can pose challenges for data integration, interoperability, and algorithm development. \\nTherefore, ensuring the quality, completeness, and standardization of data inputs is essential for training accurate \\nand reliable AI algorithms for cancer screening.  \\nAlgorithm Bias an d Generalizability: To ensure fairness, equity, and inclusivity in cancer screening practices, \\naddressing bias in AI algorithms requires careful attention to dataset selection, algorithm design, and model \\nevaluation. Algorithms trained on biased or unrepresentative datasets may exhibit algorithmic bias and generalize \\npoorly to diverse patient populations [49].  \\nRegulatory and Ethical Considerations:  Healthcare organizations must abide by regulatory standards, such as \\nthe Food and Drug Administration (FDA) guidelines for medical device approval, and implement robust data \\nprotection measures to safeguard patient confidentiality and ensure compliance with ethical norms. The use of AI-\\ndriven screening tools in clinical practice raises regulatory and ethical considerations related to patient privacy, \\ninformed consent, and liability.  \\nAdoption and Integration by Clinicians: In order to successfully integrate AI-driven screening tools into clinical \\nworkflows, clinicians must be trusted, trained, and supported. They may have doubts about the accuracy, \\napplicability, and clinical utility of AI algorithms, so in order to allay their fears, they must be educated,  given \\nevidence of the technology's effectiveness, and encouraged to work together [50].  \\nPROSPECTS & FUTURE COURSES \\nProgress in Imaging Technology:  By utilizing state -of-the-art imaging technologies, AI algorithms can detect \\nearly-stage lesions, characterize tumor biology, and guide personalized screening strategies. These developments \\npresent opportunities to improve the sensitivity and specificity of AI -driven screening tools [51]. Examples of \\nthese developments include high -resolution imaging modalities , functional imaging techniques, and molecular \\nimaging probes.  \\nIntegration of Multi -Omics Data:  By capturing molecular signatures associated with cancer initiation, \\nprogression, and response to therapy, multi -omics integration improves the accuracy and pr edictive power of AI-\\ndriven screening tools. Multi-omics data includes genomics, transcriptomics, proteomics, and metabolomics [52]. \\nThis integration allows for comprehensive risk assessment and precision screening approaches.  \\nDigital Health and Telemedicine: By utilizing digital health technologies, AI algorithms can expand the reach of \\ncancer screening programs, especially in underserved communities, rural areas, and low-resource settings, thereby \\nimproving access to early detection and intervention serv ices. AI-driven screening tools can be integrated with \\ndigital health platforms and telemedicine solutions to enable remote monitoring, patient engagement, and \\npopulation-wide screening initiatives. Artificial intelligence (AI) holds immense promise for en hancing early \\ndetection and screening of cancer by improving sensitivity, reducing false -positive rates, and personalizing risk \\nassessment. By leveraging advanced computational techniques, machine learning algorithms, and multi -modal \\ndata integration, AI-driven screening tools can optimize resource allocation, streamline workflows, and improve \\nthe overall efficiency and effectiveness of cancer screening programs. However, addressing challenges related to \\ndata quality, algorithm bias, regulatory compliance, and clinician adoption is essential for realizing the full \\npotential of AI in cancer screening and maximizing its impact on patient outcomes [53]. As AI continues to evolve \\nand become increasingly integrated into clinical practice, ongoing collaboration be tween clinicians, researchers, \\npolicymakers, and industry stakeholders is essential to drive innovation, ensure ethical deployment, and improve \\nthe accessibility and effectiveness of cancer screening efforts.  \\n \\n \", path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='87e47e1a-0f2d-41bb-b593-71fc2fc921e1', embedding=None, metadata={'page_label': '9', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text='Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 126   \\nAI APPLICATIONS FOR DRUG DEVELOPMENT AND DISCOVERY \\nTarget Identification and Validation: By integrating multi-omics data and biological knowledge databases, AI-\\ndriven approaches can prioritize candidate targets based on their relevance to cancer biology, druggability, and \\npotential therapeutic impac t. AI algorithms can analyze large -scale genomic, proteomic, and transcriptomic \\ndatasets to identify potential therapeutic targets and elucidate underlying disease mechanisms [54].  AI -driven \\napproaches can identify novel therapeutic combinations that targ et complementary pathways or overcome drug \\nresistance mechanisms in cancer by analyzing drug -target interactions, molecular pathways, and phenotypic \\nresponses. Drug Repurposing and Combination Therapy: AI algorithms can repurpose existing drugs for new \\nindications or identify synergistic drug combinations with enhanced therapeutic efficacy.  \\nMolecular Modeling and Drug Design: Artificial Intelligence-driven methods for molecular modeling, including \\nvirtual screening, molecular docking, and de novo drug desi gn, allow for the quick and economical creation of \\nnew drug candidates [55]. AI algorithms help select lead compounds with the best drug -like qualities for \\nsubsequent development by forecasting the binding affinity, pharmacokinetic characteristics, and saf ety profiles \\nof possible drug candidates.   \\nReferences \\n1. Adulyasak Y, Benomar O, Chaouachi A, Cohen M, Khern -am-nuai W (2020) Data analytics to \\ndetectbpanic buying and improve products distribution amid pandemic. Available at SSRN 3742121  \\n2. Ahmad A, Dey L (20 07) A k -mean clustering algorithm for mixed numeric and categorical data. \\nDatavKnowl Eng 63(2):503‚Äì527  \\n3. Alarie B (2016) the path of the law: towards legal singularity. Univ Toronto Law J 66(4):443 ‚Äì455  \\n4. Alarie B, Niblett A, Yoon AH (2018) How artificial int elligence will affect the practice of law. Univ \\nToronto Law J 68(s1):106‚Äì124  \\n5. Allon G, Cohen M, Sinchaisri WP (2018) the impact of behavioral and economic drivers on gig economy \\nworkers. Available at SSRN 3274628 17 ISSN: 0022-3301 | April 2023 Syed Mohd Akbar Rizvi, Tasleem \\nJamal  \\n6. Babar Y, Burtch G (2020) Examining the heterogeneous impact of ride-hailing services on public transit \\nuse. Inf Syst Res 31(3):820‚Äì834  \\n7. Burosu SH (2021) UBER drivers: employee, worker or independent contractor? https:// www. lexol ogy. \\nCom/ libra ry/ detail. aspx?g= cc848 bb3- b06d- 404c- ad29- 80846 a4f89 2a  \\n8. Chen DL, Eagel  J (2017) Can machine learning help predict the outcome of asylum adjudications? In: \\nProceedings of the 16th Edition of the International Conference on Articial Intelligence and Law, pp 237‚Äì \\n240  \\n9. Cohen MC, Dahan S, Rule C (2021) Conflict analytics: when da ta science meets dispute resolution. \\nForthcoming in Management Business Review  \\n10. Dahan S, Liang D (2020) the case for AI-powered legal aid. Queen‚Äôs LJ 46:415  \\n11. Dahan S, Touboul J, Lam J, Sfedj D (2020) Predicting employment notice period with machine learning: \\npromises and limitations. McGill Law J/Revue de droit de McGill 65(4):711 ‚Äì753  \\n12. Deakin S (2020) Decoding employment status. King‚Äôs Law J 31(2):180‚Äì193  \\n13. Deakin S, Markou C (2020) is law computable? Critical perspectives on law and artificial intelligence.  \\nBloomsbury Publishing Plc, London  \\n14. Deakin S, et al (2005) the comparative evolution of the employment relationship. Citeseer  \\n15. Dunn M, Sagun L, ≈ûirin H, Chen D (2017) early predictability of asylum court decisions. In: Proceedings \\nof the 16th Edition of the international conference on artificial intelligence and law, pp 233‚Äì 236  \\n16. Fragomeni B, Scarrow  K, MacFarlane J (2020) tracking the trends of the self -represented litigant \\nphenomenon: Data from the national self -represented litigant‚Äôs project, 2018/2019. Technical report, \\nNational Self-Represented Litigants Project  \\n17. Greenwood B, Burtch G, Carnahan S  (2017) Unknowns of the gig -economy. Commun ACM 60(7):27 ‚Äì\\n29  \\n18. Huang N, Burtch G, Hong Y, Pavlou PA (2020) Unemployment and worker participation in the gig \\neconomy: evidence from an online labor market. Inf Syst Res 31(2):431 ‚Äì448Kauffman ME, Soares \\n19. Smith, A. (2022). \"Digital Health Records: Transforming Healthcare.‚Äù Medical Journal, 58 (4), 102 - 110.  \\n20. Johnson, L., & Patel, S. (2021). \"Telemedicine in the Age of COVID - 19.‚Äù HealthTech, 34 (2), 56 - 62.  ', path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='6fff13f3-f948-496a-8aba-89aa4e869829', embedding=None, metadata={'page_label': '10', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text='Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 127   \\n21. Davis, J. (2023). \"AI in Medical Imaging: A Revolution.‚Äù AI in Healthcare, 12 (1), 45 - 50.  \\n22. Brown, T., & Green, M. (2022). \"Personalized Medicine: The Genomic Revolution.‚Äù Pharma Today, 77 \\n(5), 134 - 140.  \\n23. O\\'Reilly, K. (2023). \"Wearable Health Tech: A New Era.‚Äù Fitness & Health, 88 (3), 94 - 99.  \\n24. Li, F., & Zh ang, H. (2022). \"3D Printing in Medicine: Applications and Challenges.‚Äù Biomedical \\nEngineering, 10 (4), 88 - 95.  \\n25. Kumar, A., & Roy, D. (2021). \"Blockchain for Health Data.‚Äù Tech Innovations, 15 (6), 66 ‚Äì 73 \\n26. Edwards, R., & White, L. (2023). \"Ethical Dilemma s in Digital Health.‚Äù Ethics in Medicine, 18 (2), 110 \\n- 117.  \\n27. Nguyen, T. (2023). \"Future of Healthcare: Emerging Technologies. \" HealthTech Future, 22 (1), 76 ‚Äì 84 \\n28. Ashton\\'s article provides insights into the conceptualization of IoT and its potential impact on industries.  \\n29. Satyanarayanan, M., Bahl, P., Caceres, R., & Davies, N. (2017). The case for edge computing. IEEE \\nComputer, 50 (1), 30 - 39. (Https: //doi. org/10.1109/MC.2017.4450064)  \\n30. Zhang, Y., Zheng, D., Li, X., & Song, H. (2018). Internet of Things (IoT) data analytics. In G. Pan, M. \\nQiu, X. Li, & S. Zeadally (Eds.), Internet of Things: Principles and Paradigms (pp.391 - 422). Wiley. \\n31. Arinez JF, Chang Q, Gao RX, Xu C, Zhang J. Artificial intelligence in advanced manufacturing: Current \\nstatus and future outlook. Journal of Manufacturing Science and Engineering. 2020; 142(11). Saxena et \\nal.; J. Eng. Res. Rep., vol. 26, no. 3, pp. 49-62, 2024; Article no.JERR.113277 58  \\n32. Agrawal A, Gans JS, Goldfarb A, Exploring the impact of artificial intelligence: Predi ction versus \\njudgment. Inf Econ Policy. 2019; 1.  \\n33. Ahmed MA, Alkhamis TM. Simulation optimization for an emergency department healthcare unit in \\nKuwait. Eur J Oper Res. 2009; 198.  \\n34. Aisyah M, Cockcroft S. A snapshot of data quality issues in Indonesian commu nity health. Int J Netw \\nVirtual Organ. 2014; 14.  \\n35. Aria M, Cuccurullo C. Bibliometrix: An Rtool for comprehensive science mapping analysis. J Informetr. \\n2017; 11.  \\n36. Baig MM, et al. A systematic review of wearable patient monitoring systems ‚Äî Current challenges and \\nopportunities for clinical adoption. J Med Syst. 2017; 41 \\n37. Bennett CC, Hauser K. Artificial intelligence framework for simulating clinical decision -making: A \\nMarkov decision process approach. Artif Intell Med. 2013; 57.  \\n38. Bert F, et al. HIV screening i n pregnant women: A systematic review of costeffectiveness studies. Int J \\nHealth Plann Manag. 2018; 33.  \\n39. Biancone P, et al. Management of open innovation in healthcare for cost accounting using EHR. J Open \\nInnov Technol Market Complex. 2019; 5.  \\n40. Biancone PP, et al. Data quality methods and applications in health care system: A systematic literature \\nreview. Int J Bus Manag. 2019; 14.  \\n41. Jamal, A. (2023). Novel Approaches in the Field of Cancer Medicine.  Biological times, 2(12), 52-53. \\n42. Burton RJ, et al. Using artificial intelligence to reduce diagnostic workload without compromising \\ndetection of urinary tract infections. BMC Med Inform Decis Mak. 2019; 19.  \\n43. Carter D. How real is the impact of artificial intelligence? Bus Inf Surv. 2018; 35.  \\n44. Chakradhar S. Predictable response: Finding optimal drugs and doses using artificial intelligence. Nat \\nMed. 2017; 23.  \\n45. Chen G, Xiao L. Selecting publication keywords for domain analysis in bibliometrics: A comparison of \\nthree methods. J Informet. 2016; 10.  \\n46. Cho BJ, et al. Classification of cervical neoplasms on colposcopic photography using deep learning. Sci \\nRep. 2020; 10. Saxena et al.; J. Eng. Res. Rep., vol. 26, no. 3,  pp. 49-62, 2024; Article no.JERR.113277 \\n60  \\n47. Choudhury A, Asan O. Role of artificial intelligence in patient safety outcomes: Systematic literature \\nreview. JMIR Med Inform. 2020; 8.  \\n48. Agrawal, J. (2018). Stethee, an AI Powered Electronic Stethoscope. Anaesthesia, Pain & Intensive Care, \\n22(3), 412‚Äì413.  \\n49. Agrawal, P. (2018). Artificial intelligence in drug discovery and development. J Pharmacovigil, 6(2).  \\n50. Angus, D. C. (2020). Randomized clinical trials of artificial intelligence. Jama, 323(11), 1043 ‚Äì1045. ', path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}'),\n",
       " Document(id_='b83e48c8-1c26-4b10-ab5b-b29ec3992e26', embedding=None, metadata={'page_label': '11', 'file_name': 'Hafiz+Khawar.pdf', 'file_path': 'd:\\\\Langchain\\\\Project\\\\RP\\\\Hafiz+Khawar.pdf', 'file_type': 'application/pdf', 'file_size': 204697, 'creation_date': '2025-01-23', 'last_modified_date': '2025-01-23'}, excluded_embed_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], excluded_llm_metadata_keys=['file_name', 'file_type', 'file_size', 'creation_date', 'last_modified_date', 'last_accessed_date'], relationships={}, metadata_template='{key}: {value}', metadata_separator='\\n', text_resource=MediaResource(embeddings=None, data=None, text='Saad Rasool \\nBULLET : Jurnal Multidisiplin Ilmu  \\nVolume 3, No. 01, Februari-Maret (2024) \\nISSN 2829-2049 (media online)  \\nHal 118-128 \\nhttps://journal.mediapublikasi.id/index.php/bullet  | Page 128   \\n51. Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H., & Yuan, S. (2019). Advancing drug discovery via \\nartificial intelligence. Trends in Pharmacological Sciences, 40(8), 592‚Äì 604.  \\n52. Cruciger, O., Schildhauer, T. A., Meindl, R. C., Tegenthoff, M., Schwenkreis, P., Citak, M., & Aach, M. \\n(2016). Impact of locomotion training with a neurologic controlled hybrid assistive limb (HAL) \\nexoskeleton on neuropathic pain and health related quality of life (HRQoL) in chronic SCI: a case study. \\nDisability and Rehabilitation: Assistive Technology, 11(6), 529‚Äì534. \\n53. D√≠az, √ì. Dalton, J. A. R., & Giraldo, J. (2019). Artificial intelligence: a novel approach for drug discovery. \\nTrends in Pharmacological Sciences, 40(8), 550‚Äì551.  \\n54. Rajpurkar, P. et al. CheXNet: Radiologist -Level Pneumonia D etection on Chest X -Rays with Deep \\nLearning. arXiv [cs.CV] (2017).  \\n55. Gulshan, V. et al. Development and Validation of a Deep Learning Algorithm for Detection of Diabetic \\nRetinopathy in Retinal Fundus Photographs. JAMA 316, 2402‚Äì2410 (2016).  \\n \\n ', path=None, url=None, mimetype=None), image_resource=None, audio_resource=None, video_resource=None, text_template='{metadata_str}\\n\\n{content}')]"
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "documents"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\n",
      "Parsing nodes: 100%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| 11/11 [00:00<00:00, 337.56it/s]\n",
      "\n",
      "\u001b[A\n",
      "Generating embeddings: 100%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| 18/18 [00:06<00:00,  2.87it/s]\n"
     ]
    }
   ],
   "source": [
    "index=VectorStoreIndex.from_documents(documents,show_progress=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "<llama_index.core.indices.vector_store.base.VectorStoreIndex at 0x2057dd3a3c0>"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "index"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "query_engine=index.as_query_engine()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {},
   "outputs": [],
   "source": [
    "from llama_index.core.retrievers import VectorIndexRetriever\n",
    "from llama_index.core.query_engine import RetrieverQueryEngine\n",
    "from llama_index.core.indices.postprocessor import SimilarityPostprocessor\n",
    "\n",
    "retriever=VectorIndexRetriever(index=index,similarity_top_k=4)\n",
    "postprocessor=SimilarityPostprocessor(similarity_cutoff=0.80)\n",
    "\n",
    "query_engine=RetrieverQueryEngine(retriever=retriever,\n",
    "                                  node_postprocessors=[postprocessor])\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [],
   "source": [
    "response=query_engine.query(\"What is AI can do in cancer diagnosis?\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Final Response: AI can enhance cancer diagnosis by utilizing machine\n",
      "learning algorithms to analyze medical imaging studies, such as CT\n",
      "scans, MRIs, PET scans, and X-rays. These algorithms can accurately\n",
      "interpret radiological images, define tumor boundaries, detect\n",
      "suspicious lesions, quantify tumor characteristics, and evaluate\n",
      "treatment responses. Additionally, AI-driven screening algorithms can\n",
      "analyze various data types, including imaging studies, biomarkers, and\n",
      "patient demographics, to identify subtle patterns or anomalies\n",
      "indicative of early-stage cancer, enabling timely intervention and\n",
      "treatment initiation. Furthermore, AI-powered digital pathology\n",
      "platforms can automate slide scanning, image analysis, and diagnosis,\n",
      "improving diagnostic accuracy and efficiency in cancer diagnosis.\n",
      "______________________________________________________________________\n",
      "Source Node 1/4\n",
      "Node ID: 0c4ccca3-c9cc-460e-914f-de9a20202047\n",
      "Similarity: 0.8940921359391686\n",
      "Text: AI'S ADVANTAGES FOR EARLY DETECTION AND SCREENING   Increased\n",
      "Sensitivity and Specificity: Artificial intelligence (AI) algorithms\n",
      "have the ability to analyze intricate  patterns and features in\n",
      "medical imaging studies, including computed tomography (CT) scans,\n",
      "magnetic resonance  imaging (MRI), and mammograms, with a sensitivity\n",
      "and specificity...\n",
      "______________________________________________________________________\n",
      "Source Node 2/4\n",
      "Node ID: 652f6b29-a349-4cef-a3a8-9e67dbc745cd\n",
      "Similarity: 0.8859252658076365\n",
      "Text: AI -driven monitoring systems use advanced imaging techniques,\n",
      "molecular biomarkers, and  machine learning algorithms to provide\n",
      "real-time feedback on treatment response and disease progression.\n",
      "Additionally, circulating t umor DNA (ctDNA), circulating tumor cells\n",
      "(CTCs), and other biomarkers in blood  samples can be analyzed by AI\n",
      "-powered li...\n",
      "______________________________________________________________________\n",
      "Source Node 3/4\n",
      "Node ID: 6dca56c0-56ef-4663-a68b-844987e20ecd\n",
      "Similarity: 0.8824716329500578\n",
      "Text: Saad Rasool  BULLET : Jurnal Multidisiplin Ilmu   Volume 3, No.\n",
      "01, Februari-Maret (2024)  ISSN 2829-2049 (media online)   Hal 118-128\n",
      "https://journal.mediapublikasi.id/index.php/bullet  | Page 119\n",
      "approach helps oncologists to customize treatment plans for each\n",
      "patient, increasing therapeutic efficacy while  reducing side effects.\n",
      "Based on...\n",
      "______________________________________________________________________\n",
      "Source Node 4/4\n",
      "Node ID: 3b3ff60a-fd97-4bff-b728-349c01de105a\n",
      "Similarity: 0.8817753673991315\n",
      "Text: Machine learning (ML), a subset of AI, is the process of\n",
      "teaching algorithms to  identify patterns in data and make\n",
      "predictions. Deep learning, a more advanced application of ML, uses\n",
      "artificial  neural networks to process large amounts of data and\n",
      "extract complex features [ 2].  AI is being used in a wide  range of\n",
      "healthcare domains, such as m...\n",
      "AI can enhance cancer diagnosis by utilizing machine learning algorithms to analyze medical imaging studies, such as CT scans, MRIs, PET scans, and X-rays. These algorithms can accurately interpret radiological images, define tumor boundaries, detect suspicious lesions, quantify tumor characteristics, and evaluate treatment responses. Additionally, AI-driven screening algorithms can analyze various data types, including imaging studies, biomarkers, and patient demographics, to identify subtle patterns or anomalies indicative of early-stage cancer, enabling timely intervention and treatment initiation. Furthermore, AI-powered digital pathology platforms can automate slide scanning, image analysis, and diagnosis, improving diagnostic accuracy and efficiency in cancer diagnosis.\n"
     ]
    }
   ],
   "source": [
    "from llama_index.core.response.pprint_utils import pprint_response\n",
    "pprint_response(response,show_source=True)\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "Generating embeddings:  94%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñç| 17/18 [21:55<01:17, 77.39s/it]\n",
      "Generating embeddings:  94%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñç| 17/18 [19:05<01:07, 67.41s/it]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "The future prospect for AI in cancer diagnosis involves further advancements in medical imaging and image analysis, algorithms for early detection and screening, interpretation of pathology and histopathology, and AI-driven monitoring systems. These advancements aim to enhance accuracy, efficiency, early detection, and personalized treatment strategies in cancer diagnosis, ultimately improving patient outcomes and transforming the field of oncology.\n"
     ]
    }
   ],
   "source": [
    "import os.path\n",
    "from llama_index.core import (\n",
    "    VectorStoreIndex,\n",
    "    SimpleDirectoryReader,\n",
    "    StorageContext,\n",
    "    load_index_from_storage,\n",
    ")\n",
    "\n",
    "# check if storage already exists\n",
    "PERSIST_DIR = \"./storage\"\n",
    "if not os.path.exists(PERSIST_DIR):\n",
    "    # load the documents and create the index\n",
    "    documents = SimpleDirectoryReader(\"RP\").load_data()\n",
    "    index = VectorStoreIndex.from_documents(documents)\n",
    "    # store it for later\n",
    "    index.storage_context.persist(persist_dir=PERSIST_DIR)\n",
    "else:\n",
    "    # load the existing index\n",
    "    storage_context = StorageContext.from_defaults(persist_dir=PERSIST_DIR)\n",
    "    index = load_index_from_storage(storage_context)\n",
    "\n",
    "# either way we can now query the index\n",
    "query_engine = index.as_query_engine()\n",
    "response = query_engine.query(\"What is the future prospect for AI in cancer diagnosis?\")\n",
    "print(response)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
